Armata Pharmaceuticals (FRA:TG1N) EV-to-Revenue : (As of May. 22, 2024)

View and export this data going back to . Start your Free Trial

What is Armata Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Armata Pharmaceuticals's enterprise value is €205.31 Mil. Armata Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil. Therefore, Armata Pharmaceuticals's EV-to-Revenue for today is .

The historical rank and industry rank for Armata Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

During the past 13 years, the highest EV-to-Revenue of Armata Pharmaceuticals was 3055.42. The lowest was -2519.92. And the median was 391.29.

FRA:TG1N's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.21
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-22), Armata Pharmaceuticals's stock price is €2.42. Armata Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Therefore, Armata Pharmaceuticals's PS Ratio for today is .

Armata Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Armata Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armata Pharmaceuticals EV-to-Revenue Chart

Armata Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

Armata Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Armata Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Armata Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Armata Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's EV-to-Revenue falls into.

Armata Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Armata Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	205.310	/	0
	=

Armata Pharmaceuticals's current Enterprise Value is €205.31 Mil.
Armata Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Armata Pharmaceuticals (FRA:TG1N) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Armata Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	2.42	/	0
	=

Armata Pharmaceuticals's share price for today is €2.42.
Armata Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

Armata Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Armata Pharmaceuticals (FRA:TG1N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (FRA:TG1N) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

ARMP:USA TG1M:Germany

Address

4503 Glencoe Avenue, Marina del Rey, CA, USA, 90292

Website

https://www.armatapharma.com

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Armata Pharmaceuticals (FRA:TG1N) Headlines

No Headlines